LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

Insulet Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

292.78 1.22

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

289.36

Max

299.12

Pagrindiniai rodikliai

By Trading Economics

Pajamos

65M

88M

Pardavimai

57M

706M

P/E

Sektoriaus vid.

86.246

76.798

Pelnas, tenkantis vienai akcijai

1.24

Pelno marža

12.403

Darbuotojai

3,900

EBITDA

90M

160M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+28.24% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.9B

21B

Ankstesnė atidarymo kaina

291.56

Ankstesnė uždarymo kaina

292.78

Naujienos nuotaikos

By Acuity

31%

69%

80 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Insulet Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-18 23:54; UTC

Karštos akcijos

Stocks to Watch: Nike, Cassava Sciences, KB Home

2025-12-18 23:51; UTC

Uždarbis

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

2025-12-18 23:39; UTC

Pagrindinės rinkos jėgos

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

2025-12-18 22:57; UTC

Įsigijimai, susijungimai, perėmimai

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

2025-12-18 21:40; UTC

Uždarbis

Nike Sales Tick Up, But China Weakness Persists

2025-12-18 23:45; UTC

Rinkos pokalbiai

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

2025-12-18 23:37; UTC

Rinkos pokalbiai
Uždarbis

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

2025-12-18 23:36; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

2025-12-18 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

2025-12-18 23:02; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

2025-12-18 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

2025-12-18 22:59; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

2025-12-18 22:58; UTC

Įsigijimai, susijungimai, perėmimai

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

2025-12-18 22:57; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

2025-12-18 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

2025-12-18 22:55; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:59; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-12-18 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-18 21:35; UTC

Uždarbis

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025-12-18 21:31; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Greater China Rev Down 17% >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q EPS 53c >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Apparel Rev $3.91B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Equipment Rev $550M >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q N Amer Rev $5.63B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Footwear Rev $7.66B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Greater China Rev $1.42B >NKE

Akcijų palyginimas

Kainos pokytis

Insulet Corp Prognozė

Kainos tikslas

By TipRanks

28.24% į viršų

12 mėnesių prognozė

Vidutinis 375.59 USD  28.24%

Aukščiausias 450 USD

Žemiausias 316 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Insulet Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

17

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

252.29 / 259.38Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

80 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
help-icon Live chat